Efficacy and Acceptance of Cognitive Behavioral Therapy in Adults with Chronic Fatigue Syndrome: A Meta-analysis.
Open accessThe DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index; 26 of the 66 sources its claims cite were checked for support.
Abstract
Background: The systematic aggregation of research on cognitive behavioral therapy (CBT) in chronic fatigue syndrome (CFS) needs an update. Although meta-analyses evaluating interventions typically focus on symptom reduction, they should also consider indicators of treatment acceptability, e.g., drop-out rates. Methods: Randomized controlled trials (RCTs) investigating CBT in adults with CFS compared to inactive and non-specific control groups were included. First, efficacy was examined, considering fatigue, depression, anxiety, and perceived health. Secondly, drop-out rates through different trial stages were analyzed: Non-completion of all mandatory sessions, drop-out (primary study definition), treatment refusal (non-starters), and average of sessions completed. Result: We included 15 RCTs with 2015 participants. CBT was more effective than controls in fatigue (g = -0.52, 95%CI -0.69 to -0.35), perceived health, depression, and anxiety at post-treatment. At long-term follow-up the effects were maintained for fatigue and anxiety. Rates of non-completion (22%, 95%CI 3–71), drop-out (15%, 95%CI 9–25), and treatment refusal (7%, 95%CI 3–15) were relatively low, with a high average proportion of sessions completed. Total time of therapy moderated the effect on fatigue, while the number of sessions moderated the effect on perceived health. Fatigue severity influenced adherence. Conclusion: The results indicate that CBT for CFS is effective in reducing fatigue, fatigue related impairment, and severity of depression and anxiety. Conclusions on efficacy at follow-ups are still limited. However, adherence is high in CBT. The results may help to inform clinical practice. Future research should focus on examining the maintenance of effects, while also emphasizing the importance of treatment acceptance.
Overview
CoChat Summary
## TL;DR
This meta-analysis of 15 RCTs (n = 2015) found that CBT for adults with chronic fatigue syndrome reduced fatigue and improved several related outcomes at post-treatment, with some effects persisting at follow-up. The paper also found generally high treatment acceptance, with 7% treatment refusal, 15% drop-out, and 22% non-completion.
## Key findings
- CBT was more effective than controls for fatigue at post-treatment: Hedges’ g = -0.52 (95% CI -0.69 to -0.35) based on k = 11 studies.
- At long-term follow-up (k = 7; mean follow-up 31.14 weeks, SD = 12.75), the fatigue effect remained significant: g = -0.41 (95% CI -0.65 to -0.18).
- At post-treatment, CBT also improved perceived health, depression, and anxiety; at long-term follow-up, fatigue and anxiety effects were maintained, while depression and perceived health were not significant.
- Acceptance outcomes were relatively favorable: non-completion was 22% (95% CI 3–71), drop-out 15% (95% CI 9–25), treatment refusal 7% (95% CI 3–15), and the average proportion of sessions completed was 84% (95% CI 56–96).
## Methods
- Meta-analysis of randomized controlled trials in adults (≥18 years) with chronic fatigue syndrome; CBT was compared with inactive or non-specific control groups, and only studies with at least n ≥ 10 per relevant arm and published in English or German were eligible.
- Searches were run in six databases (PubMed, PsycINFO, PSYNDEX, CENTRAL, CDSR, CCA) up to 1 June 2022; 15 RCTs with 2015 participants were included.
- Random-effects meta-analyses were used for efficacy and acceptance; heterogeneity was assessed with I², and moderator analyses examined control group type, therapy setting, therapy dose, number of sessions, duration, fatigue severity, and symptom duration.
## Limitations
- The paper states that follow-up conclusions are limited because the evidence base at follow-up was smaller than at post-treatment, and that some outcomes still had relatively small sample sizes, especially depression and anxiety.
- The paper states that included studies mostly came from Europe and the US, and participants had already agreed to join CBT RCTs, which may limit generalizability and introduce selection bias.
- Evident from the text: many acceptance outcomes were inconsistently reported, reasons for drop-out were “rarely reported,” and definitions of drop-out/non-completion varied across studies, which the authors say can bias interpretation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 PRISMA 2020 flow diagram (adapted from Page et al. [21])](https://figures.cochat.ai/paper-figures/1080f07296ca49188e6cf4e69cfdb6d6/efficacy-and-acceptance-of-cognitive-behavioral-therapy-in-adults-with-chronic-figure-1.jpg)


Verification
Claims the paper makes
21 Valid · 1 Not valid · 25 Not checked · 97 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“A recent systematic review showed that several studies have been published since then, that could provide valuable information [16].”
§ Efficacy and Acceptance of Cognitive Behavioral Therapy in Adults with Chronic Fatigue Syndrome: A Meta-analysis > Introduction Chronic fatigue syndrome (CFS) is a debilitating disorder characterized by medically evaluated, unexplained, persistent or recurrent persistent fatigue that is not the result of current stress, not relieved by rest, results in significant activity limitations, and for which there is no clear organic explanation [1]. However, there is a broad array of possible diagnostic criteria that can be used for CFS. Hence, CFS according to the presented definition needs to be differentiated from newer classification approaches for myalgic encephalomyelitis/CFS [2]. While the etiology of CFS remains unclear, evidence suggests that not only biological but also psychosocial factors play an important role in the development and maintenance of the condition [3]. Cognitive behavioral therapy (CBT) derives from corresponding disorder models that assume interactions among biological/physical, psychological, and social factors [4]. CBT has been shown to be one of the most effective psychological treatments for CFS. In CFS, CBT is based on assumptions about the interaction of cognitive processes and behaviors, which contribute to the perpetuation of the ailments. It usually involves identifying the patient's negative thoughts, beliefs [5], and behaviors believed to contribute to the physical symptoms [6], most importantly, patients’ focus on perceived symptoms of fatigue is decreased [7]. The therapist helps the patient develop altered and more realistic views on their illness, and coping skills to manage their symptoms [8]. Thus, patients experience reversibility of symptoms, which results in enhanced self-efficacy [9]. The goal is to help patients gradually increase their activity levels and thereby to decrease impairments (e.g., [8]). Previous studies indicate short-term efficacy of CBT in reducing symptoms, enhancing quality of life, and improving physical functioning in patients with CFS. However, the evidence base for the long-term efficacy remains unclear [10]. Several previous meta-analyses have examined the efficacy of CBT in the treatment of CFS. Malouff et al.’s [11] meta-analysis (k = 13) found significant reductions in fatigue for CBT compared with inactive and non-specific control conditions (d = 0.54, 95%CI 0.26 to 0.81). Functioning was significantly reduced in subjective (d = 0.45, 95%CI 0.12 to 0.78) as well as objective measures (d = 0.52, 95%CI 0.28 to 0.76). However, not all evaluated interventions entailed cognitive components. The Cochrane review (k = 15) by Price et al. [8] resulted in small to moderate effects, e.g., for fatigue severity (SMD = -0.39, 95% CI -0.0.60 to -0.19), physical functioning (SMD = 0.11, 95%CI -0.32 to 0.54), depression (SMD = -0.24, 95%CI -0.53 to 0.05), and anxiety symptoms (SMD = -0.30, 95%CI -0.59 to -0.01) compared with inactive control conditions. Although meta-analytic results indicate significant efficacy in fatigue, functional impairment/quality of life, depression, and anxiety at short-term follow-up, long-term efficacy remains largely unclear [8, 12]. Despite these positive findings, the use of CBT as a treatment for CFS is controversial. The preceding version of the National Institute for Health and Care Excellence (NICE) guideline [13] recommended CBT for myalgic encephalomyelitis/CFS. However, the updated guideline published in 2021 [14] no longer recommends CBT as a curative, but only as an adjunctive treatment. This change has generated debate and criticism, in part due to the methods chosen by NICE to make the decision [15]. The debate highlights the need for up-to-date research on the efficacy of CBT in the treatment of CFS. Previous meta-analyses point to the short-term efficacy of CBT for CFS [8, 11, 12]. However, their publication dates back 10 to 15 years, so their results may now be outdated and not fully representative of the current state of research. A recent systematic review showed that several studies have been published since then, that could provide valuable information [16]. Furthermore, patient acceptance is an important factor in the evaluation of CFS treatment. In this context, patient acceptance of psychological treatments is of interest. If a treatment is not acceptable to patients despite demonstrated positive outcomes, it may not be effective in practice [17]. In research, drop-out might decrease the validity of the conclusions drawn from clinical trials. It is possible that it leads to a form of selection bias within randomized controlled trials [18], when people refuse to start or finish a therapy. Furthermore, psychotherapies might not work in full effect, when not adequately completed. Therefore, non-adherence can have negative consequences for patients and can increase health care costs [17]. For CFS, the review by Price et al. [8] reported an odds ratio of 1.77 (95%CI 1.13 to 2.75) for drop-out of the intervention arms compared to usual care. Malouff et al. [11] reported a mean CBT drop-out rate of 12% with a range of 0–42%. Castell et al. [12] found a median drop-out rate of 17% with a range of 0–46%. However, none of these meta-analyses differentiated between different stages of drop-out; they conferred to the authors’ definitions of drop-out which are not necessarily pre-defined or uniform. Hence, the implications that can be drawn from these results are limited. One reason for the lack of willingness to engage in psychological therapy could be the discrepancy between the subjective explanatory concepts of some people with CFS and CBT models. That is, patients that suffer from CFS often have their own explanations about the causes and nature of their illness. When these subjective explanatory models are primarily physical and not related to psychological processes (such as appraisals and dysfunctional coping behavior), they may be hesitant to engage in a therapy that emphasizes these aspects [19]. Furthermore, patient characteristics like fatigue severity or comorbid psychopathology could determine whether a patient is able and willing to participate in CBT (e.g., [20]). Other aspects of the treatment itself, such as format in individual or group intervention, might influence the acceptability of treatments for patients as well [8]. Therefore, an updated meta-analysis should examine not only the efficacy of CBT, but also its acceptability to patients. To address these questions, first, a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of CBT in adults with CFS was conducted. Our objective was to evaluate the outcomes fatigue, depression, anxiety, and functional impairment post-treatment and to determine whether these effects persist in the long term. Secondly, we analyzed acceptance of CBT in a very differentiated way, i.e., drop-out rates at different stages of the trials. Here, the primary outcomes were non-completion of all mandatory sessions, and drop-out according to the primary study definition. Additionally, treatment refusal (non-starters), and the average number of sessions completed were included. Besides, for both parts of the project, differentiated moderator analyses served to identify the impact of study design, treatment format and participant characteristics on treatment efficacy and acceptance, e.g., regarding the different diagnostic criteria and control groups used in the studies, intervention related variables (treatment intensity and therapy setting), and – for the acceptance analyses – clinical variables (fatigue severity and duration of fatigue symptoms).
What the sources say
- Supportedcites [16] Ingman T, Smakowski A, Goldsmith K, Chalder T. A systematic literature review of randomized controlled trials evaluating prognosis following treatment for adults with chronic fatigue syndrome. Psychol Med. 2022;52:2917–29. https://doi.org/10.1017/S0033291722002471. source
The Methods section names earlier meta-analytic reviews, including reviews from 2008, 2011 and 2015. The Results section includes later studies, including trials published in 2016, 2017 and 2019, supporting the point that newer studies could inform a review. The indexed passages provide no page numbers. (LLM, conf=0.84)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For follow-ups longer than 12 months post-treatment, two studies provided information on fatigue severity: [45] reported a ~ 3.5-year follow-up to [46] (g = 0.12, 95%CI -0.23 to 0.47), and [47] reported a two-year follow-up to [42] (g = -0.21, 95%CI -0.47 to 0.05).”
§ Efficacy and Acceptance of Cognitive Behavioral Therapy in Adults with Chronic Fatigue Syndrome: A Meta-analysis > Results > Efficacy of CBT
What the sources say
- Not checked — no full text of the sourcecites [45] Leone SS, Huibers MJH, Kant I, et al. Long-term efficacy of cognitive-behavioral therapy by general practitioners for fatigue: a 4-year follow-up study. J Psychosom Res. 2006;61:601–7. https://doi.org/10.1016/j.jpsychores.2006.04.010. source
- Supportedcites [46] *Huibers MJH, Beurskens AJHM, van Schayck CP, et al. Efficacy of cognitive-behavioural therapy by general practitioners for unexplained fatigue among employees: Randomised controlled trial. Br J Psychiatry. 2004;184:240–6. https://doi.org/10.1192/bjp.184.3.240. source
The cited paper is used as [42] to identify the original trial, not as the source of the two-year effect estimate, which the sentence attributes to [47]. Its Outcome assessment and Outcomes sections describe fatigue-severity measurements through a 12-month follow-up, consistent with its role as the original study. No page number is available in our copy. (LLM, conf=0.83)
- Partly supportedcites [47] Sharpe M, Goldsmith KA, Johnson AL, Chalder T, Walker J, White PD. Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial. Lancet Psychiatry. 2015;2:1067–74. https://doi.org/10.1016/S2215-0366(15)00317-X. sourceExperimental — accuracy not yet measured
The long-term follow-up sample section reports assessment a median of 31 months after randomisation, and Differences between randomised treatment groups at long-term follow-up reports no significant difference in mean fatigue scores. This supports the PACE follow-up portion of the citing sentence, but our copy does not report the attributed g = -0.21 or its 95% CI; the other effect estimate belongs to a separately cited study. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While the etiology of CFS remains unclear, evidence suggests that not only biological but also psychosocial factors play an important role in the development and maintenance of the condition [3].”
§ Efficacy and Acceptance of Cognitive Behavioral Therapy in Adults with Chronic Fatigue Syndrome: A Meta-analysis > Introduction Chronic fatigue syndrome (CFS) is a debilitating disorder characterized by medically evaluated, unexplained, persistent or recurrent persistent fatigue that is not the result of current stress, not relieved by rest, results in significant activity limitations, and for which there is no clear organic explanation [1]. However, there is a broad array of possible diagnostic criteria that can be used for CFS. Hence, CFS according to the presented definition needs to be differentiated from newer classification approaches for myalgic encephalomyelitis/CFS [2]. While the etiology of CFS remains unclear, evidence suggests that not only biological but also psychosocial factors play an important role in the development and maintenance of the condition [3]. Cognitive behavioral therapy (CBT) derives from corresponding disorder models that assume interactions among biological/physical, psychological, and social factors [4]. CBT has been shown to be one of the most effective psychological treatments for CFS. In CFS, CBT is based on assumptions about the interaction of cognitive processes and behaviors, which contribute to the perpetuation of the ailments. It usually involves identifying the patient's negative thoughts, beliefs [5], and behaviors believed to contribute to the physical symptoms [6], most importantly, patients’ focus on perceived symptoms of fatigue is decreased [7]. The therapist helps the patient develop altered and more realistic views on their illness, and coping skills to manage their symptoms [8]. Thus, patients experience reversibility of symptoms, which results in enhanced self-efficacy [9]. The goal is to help patients gradually increase their activity levels and thereby to decrease impairments (e.g., [8]). Previous studies indicate short-term efficacy of CBT in reducing symptoms, enhancing quality of life, and improving physical functioning in patients with CFS. However, the evidence base for the long-term efficacy remains unclear [10]. Several previous meta-analyses have examined the efficacy of CBT in the treatment of CFS. Malouff et al.’s [11] meta-analysis (k = 13) found significant reductions in fatigue for CBT compared with inactive and non-specific control conditions (d = 0.54, 95%CI 0.26 to 0.81). Functioning was significantly reduced in subjective (d = 0.45, 95%CI 0.12 to 0.78) as well as objective measures (d = 0.52, 95%CI 0.28 to 0.76). However, not all evaluated interventions entailed cognitive components. The Cochrane review (k = 15) by Price et al. [8] resulted in small to moderate effects, e.g., for fatigue severity (SMD = -0.39, 95% CI -0.0.60 to -0.19), physical functioning (SMD = 0.11, 95%CI -0.32 to 0.54), depression (SMD = -0.24, 95%CI -0.53 to 0.05), and anxiety symptoms (SMD = -0.30, 95%CI -0.59 to -0.01) compared with inactive control conditions. Although meta-analytic results indicate significant efficacy in fatigue, functional impairment/quality of life, depression, and anxiety at short-term follow-up, long-term efficacy remains largely unclear [8, 12]. Despite these positive findings, the use of CBT as a treatment for CFS is controversial. The preceding version of the National Institute for Health and Care Excellence (NICE) guideline [13] recommended CBT for myalgic encephalomyelitis/CFS. However, the updated guideline published in 2021 [14] no longer recommends CBT as a curative, but only as an adjunctive treatment. This change has generated debate and criticism, in part due to the methods chosen by NICE to make the decision [15]. The debate highlights the need for up-to-date research on the efficacy of CBT in the treatment of CFS. Previous meta-analyses point to the short-term efficacy of CBT for CFS [8, 11, 12]. However, their publication dates back 10 to 15 years, so their results may now be outdated and not fully representative of the current state of research. A recent systematic review showed that several studies have been published since then, that could provide valuable information [16]. Furthermore, patient acceptance is an important factor in the evaluation of CFS treatment. In this context, patient acceptance of psychological treatments is of interest. If a treatment is not acceptable to patients despite demonstrated positive outcomes, it may not be effective in practice [17]. In research, drop-out might decrease the validity of the conclusions drawn from clinical trials. It is possible that it leads to a form of selection bias within randomized controlled trials [18], when people refuse to start or finish a therapy. Furthermore, psychotherapies might not work in full effect, when not adequately completed. Therefore, non-adherence can have negative consequences for patients and can increase health care costs [17]. For CFS, the review by Price et al. [8] reported an odds ratio of 1.77 (95%CI 1.13 to 2.75) for drop-out of the intervention arms compared to usual care. Malouff et al. [11] reported a mean CBT drop-out rate of 12% with a range of 0–42%. Castell et al. [12] found a median drop-out rate of 17% with a range of 0–46%. However, none of these meta-analyses differentiated between different stages of drop-out; they conferred to the authors’ definitions of drop-out which are not necessarily pre-defined or uniform. Hence, the implications that can be drawn from these results are limited. One reason for the lack of willingness to engage in psychological therapy could be the discrepancy between the subjective explanatory concepts of some people with CFS and CBT models. That is, patients that suffer from CFS often have their own explanations about the causes and nature of their illness. When these subjective explanatory models are primarily physical and not related to psychological processes (such as appraisals and dysfunctional coping behavior), they may be hesitant to engage in a therapy that emphasizes these aspects [19]. Furthermore, patient characteristics like fatigue severity or comorbid psychopathology could determine whether a patient is able and willing to participate in CBT (e.g., [20]). Other aspects of the treatment itself, such as format in individual or group intervention, might influence the acceptability of treatments for patients as well [8]. Therefore, an updated meta-analysis should examine not only the efficacy of CBT, but also its acceptability to patients. To address these questions, first, a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of CBT in adults with CFS was conducted. Our objective was to evaluate the outcomes fatigue, depression, anxiety, and functional impairment post-treatment and to determine whether these effects persist in the long term. Secondly, we analyzed acceptance of CBT in a very differentiated way, i.e., drop-out rates at different stages of the trials. Here, the primary outcomes were non-completion of all mandatory sessions, and drop-out according to the primary study definition. Additionally, treatment refusal (non-starters), and the average number of sessions completed were included. Besides, for both parts of the project, differentiated moderator analyses served to identify the impact of study design, treatment format and participant characteristics on treatment efficacy and acceptance, e.g., regarding the different diagnostic criteria and control groups used in the studies, intervention related variables (treatment intensity and therapy setting), and – for the acceptance analyses – clinical variables (fatigue severity and duration of fatigue symptoms).
What the sources say
- Partly supportedcites [3] Kleinstäuber M, Schröder A, Daehler S, et al. Aetiological understanding of fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome and classificatory analogues: A systematic umbrella review. Clin Psychol Eur. 2023. https://doi.org/10.32872/cpe.11179. sourceExperimental — accuracy not yet measured
The Results (Predominant Aetiological Approach; page unavailable) show that reviews investigated both biological and psychosocial factors in CFS/ME, and the Discussion (Statement of Principal Findings; page unavailable) says a few high-quality reviews suggest both types can increase the risk of functional somatic syndromes. That broader finding does not establish that both play an important role specifically in the development and maintenance of CFS; the discussion describes perpetuating factors as a potential area of interest, not an established finding. (LLM, conf=0.83)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In research, drop-out might decrease the validity of the conclusions drawn from clinical trials. It is possible that it leads to a form of selection bias within randomized controlled trials [18], when people refuse to start or finish a therapy.”
§ Efficacy and Acceptance of Cognitive Behavioral Therapy in Adults with Chronic Fatigue Syndrome: A Meta-analysis > Introduction Chronic fatigue syndrome (CFS) is a debilitating disorder characterized by medically evaluated, unexplained, persistent or recurrent persistent fatigue that is not the result of current stress, not relieved by rest, results in significant activity limitations, and for which there is no clear organic explanation [1]. However, there is a broad array of possible diagnostic criteria that can be used for CFS. Hence, CFS according to the presented definition needs to be differentiated from newer classification approaches for myalgic encephalomyelitis/CFS [2]. While the etiology of CFS remains unclear, evidence suggests that not only biological but also psychosocial factors play an important role in the development and maintenance of the condition [3]. Cognitive behavioral therapy (CBT) derives from corresponding disorder models that assume interactions among biological/physical, psychological, and social factors [4]. CBT has been shown to be one of the most effective psychological treatments for CFS. In CFS, CBT is based on assumptions about the interaction of cognitive processes and behaviors, which contribute to the perpetuation of the ailments. It usually involves identifying the patient's negative thoughts, beliefs [5], and behaviors believed to contribute to the physical symptoms [6], most importantly, patients’ focus on perceived symptoms of fatigue is decreased [7]. The therapist helps the patient develop altered and more realistic views on their illness, and coping skills to manage their symptoms [8]. Thus, patients experience reversibility of symptoms, which results in enhanced self-efficacy [9]. The goal is to help patients gradually increase their activity levels and thereby to decrease impairments (e.g., [8]). Previous studies indicate short-term efficacy of CBT in reducing symptoms, enhancing quality of life, and improving physical functioning in patients with CFS. However, the evidence base for the long-term efficacy remains unclear [10]. Several previous meta-analyses have examined the efficacy of CBT in the treatment of CFS. Malouff et al.’s [11] meta-analysis (k = 13) found significant reductions in fatigue for CBT compared with inactive and non-specific control conditions (d = 0.54, 95%CI 0.26 to 0.81). Functioning was significantly reduced in subjective (d = 0.45, 95%CI 0.12 to 0.78) as well as objective measures (d = 0.52, 95%CI 0.28 to 0.76). However, not all evaluated interventions entailed cognitive components. The Cochrane review (k = 15) by Price et al. [8] resulted in small to moderate effects, e.g., for fatigue severity (SMD = -0.39, 95% CI -0.0.60 to -0.19), physical functioning (SMD = 0.11, 95%CI -0.32 to 0.54), depression (SMD = -0.24, 95%CI -0.53 to 0.05), and anxiety symptoms (SMD = -0.30, 95%CI -0.59 to -0.01) compared with inactive control conditions. Although meta-analytic results indicate significant efficacy in fatigue, functional impairment/quality of life, depression, and anxiety at short-term follow-up, long-term efficacy remains largely unclear [8, 12]. Despite these positive findings, the use of CBT as a treatment for CFS is controversial. The preceding version of the National Institute for Health and Care Excellence (NICE) guideline [13] recommended CBT for myalgic encephalomyelitis/CFS. However, the updated guideline published in 2021 [14] no longer recommends CBT as a curative, but only as an adjunctive treatment. This change has generated debate and criticism, in part due to the methods chosen by NICE to make the decision [15]. The debate highlights the need for up-to-date research on the efficacy of CBT in the treatment of CFS. Previous meta-analyses point to the short-term efficacy of CBT for CFS [8, 11, 12]. However, their publication dates back 10 to 15 years, so their results may now be outdated and not fully representative of the current state of research. A recent systematic review showed that several studies have been published since then, that could provide valuable information [16]. Furthermore, patient acceptance is an important factor in the evaluation of CFS treatment. In this context, patient acceptance of psychological treatments is of interest. If a treatment is not acceptable to patients despite demonstrated positive outcomes, it may not be effective in practice [17]. In research, drop-out might decrease the validity of the conclusions drawn from clinical trials. It is possible that it leads to a form of selection bias within randomized controlled trials [18], when people refuse to start or finish a therapy. Furthermore, psychotherapies might not work in full effect, when not adequately completed. Therefore, non-adherence can have negative consequences for patients and can increase health care costs [17]. For CFS, the review by Price et al. [8] reported an odds ratio of 1.77 (95%CI 1.13 to 2.75) for drop-out of the intervention arms compared to usual care. Malouff et al. [11] reported a mean CBT drop-out rate of 12% with a range of 0–42%. Castell et al. [12] found a median drop-out rate of 17% with a range of 0–46%. However, none of these meta-analyses differentiated between different stages of drop-out; they conferred to the authors’ definitions of drop-out which are not necessarily pre-defined or uniform. Hence, the implications that can be drawn from these results are limited. One reason for the lack of willingness to engage in psychological therapy could be the discrepancy between the subjective explanatory concepts of some people with CFS and CBT models. That is, patients that suffer from CFS often have their own explanations about the causes and nature of their illness. When these subjective explanatory models are primarily physical and not related to psychological processes (such as appraisals and dysfunctional coping behavior), they may be hesitant to engage in a therapy that emphasizes these aspects [19]. Furthermore, patient characteristics like fatigue severity or comorbid psychopathology could determine whether a patient is able and willing to participate in CBT (e.g., [20]). Other aspects of the treatment itself, such as format in individual or group intervention, might influence the acceptability of treatments for patients as well [8]. Therefore, an updated meta-analysis should examine not only the efficacy of CBT, but also its acceptability to patients. To address these questions, first, a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of CBT in adults with CFS was conducted. Our objective was to evaluate the outcomes fatigue, depression, anxiety, and functional impairment post-treatment and to determine whether these effects persist in the long term. Secondly, we analyzed acceptance of CBT in a very differentiated way, i.e., drop-out rates at different stages of the trials. Here, the primary outcomes were non-completion of all mandatory sessions, and drop-out according to the primary study definition. Additionally, treatment refusal (non-starters), and the average number of sessions completed were included. Besides, for both parts of the project, differentiated moderator analyses served to identify the impact of study design, treatment format and participant characteristics on treatment efficacy and acceptance, e.g., regarding the different diagnostic criteria and control groups used in the studies, intervention related variables (treatment intensity and therapy setting), and – for the acceptance analyses – clinical variables (fatigue severity and duration of fatigue symptoms).
What the sources say
- Supportedcites [18] Eysenbach G. The law of attrition. J Med Internet Res. 2005;7:e11. https://doi.org/10.2196/jmir.7.1.e11. source
In “Dealing With Attrition: ITT and ‘Run-In and Withdrawal Design,’” the paper explicitly says dropout threatens validity because it may introduce selection bias. It explains that differential dropout between trial groups can distort outcomes measured among the remaining participants. (LLM, conf=0.94)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While cases of clinically relevant worsening of symptoms due to CBT are rather rare in CFS [16], they might still have an increased risk of dropping out of treatment.”
§ Efficacy and Acceptance of Cognitive Behavioral Therapy in Adults with Chronic Fatigue Syndrome: A Meta-analysis > Discussion The results of this meta-analysis provide important insights into the efficacy and acceptance of CBT in the treatment of CFS in adults. Our findings confirm that CBT is an effective intervention for CFS. We found significant post-treatment effects of CBT on fatigue, depression, anxiety, and perceived health status. The effect on the primary efficacy outcome, fatigue, was moderate with a confidence interval ranging from small to moderate effects. The mean effects on the other efficacy outcomes were smaller, yet had wider confidence intervals. That is, there were small effects on depression, anxiety, and perceived health status in CBT compared to inactive and non-specific control groups. The follow-up effects suggest a partial maintenance, while the data base is slightly smaller than for post-treatment. The effect on fatigue was small with the upper end of the 95%CI ranging into moderate effects. For the secondary outcomes, neither the effect on depression nor on perceived health status was significant at long-term follow-up. In contrast, there was a small significant overall effect on anxiety. All in all, these results are in line with previous research [8, 11, 12, 16, 49], indicating that CBT can alleviate CFS symptoms and improve patients’ overall well-being. In fact, this analysis is based on a broader data base compared to previous meta-analyses. Yet, for some outcomes sample sizes are still relatively small. This is especially the case for depression and anxiety. Besides, this is the first project that provides meaningful aggregated long-term effects; in previous works, there were only short-term follow-up effects [8] or aggregation was not possible [12]. While there is a recently published individual patient data meta-analysis in CBT for CFS [49], the data base for that project was limited to a specific treatment-protocol (e.g., [50]) and therefore less generalizable. In the light of the latest NICE guidelines [14], this meta-analysis sheds light on the acceptance of CBT in the treatment of CFS, which is an important aspect of treatment evaluation. The results showed that non-adherence rates in the CBT group were generally low, indicating that CBT was acceptable to patients. Over all studies, only 7% of participants refused participation after randomization. Of those who started the interventions, a mean of 15% dropped out of the treatment groups, and 22% did not complete all mandatory modules. That is, most participants completed all mandatory modules and even more received an adequate amount of treatment according to the individual study authors’ definitions. In line with this, some studies that reported the average proportion of sessions completed, and the aggregated rates indicate that patients on average complete most sessions. Although some clinicians argue that some patients discontinue treatment due to major improvements already made during the current path of treatment, this is rather unlikely [51]. While cases of clinically relevant worsening of symptoms due to CBT are rather rare in CFS [16], they might still have an increased risk of dropping out of treatment. In general, about one fifth of participants drop out of psychotherapy trials [28, 52]. That is, the findings on drop-out in this project are comparable to general reviews on drop-out in psychotherapy studies. Furthermore, the results on treatment refusal are comparable to treatment refusal rates in individual therapies for various psychological disorders as well [28]. In non-completion, the RR was not significant between intervention and control groups, but the confidence interval was wide, and heterogeneity was considerable. In contrast, the RR for drop-out was significantly larger in intervention groups, i.e., participants were more than twice as likely to drop-out of the intervention groups compared to the controls. Heterogeneity was moderate to considerable. However, in the non-specific, and especially in the inactive control groups, the definitions of dropping out of the control group and non-completion in the control group were not always clearly defined. Moreover, in most control groups, participation was low-threshold due to the inactive nature. Hence, the RRs cannot be adequately interpreted as they are most likely biased by this methodological artifact. The reported analyses on efficacy and acceptance provide average effects, thereby complementing another recent review [16] that reported the proportion of clinically improved or worsened cases. Furthermore, the results of most analyses in this project showed a relevant amount of heterogeneity. This suggests that not every patient benefits from CBT, which is why an array of moderators was examined: Using moderator and sensitivity analyses, the effects on fatigue were larger when only compared to inactive control groups (moderate to large effect). However, the effects were still small to moderate, if CBT was compared to an intervention that controls for some factors such as therapist support, attention, or expectancy variables. Within the subgroup analyses, the 95%CIs of both groups did not overlap and heterogeneity was drastically reduced in both groups. There was a similar pattern for perceived health status, as the effect was only significant for inactive control groups, but not for non-specific control groups with a larger 95%CI for the latter (from no effect to a moderate effect). Yet, the subgroups did not differ significantly. For perceived health status, the therapy setting (group vs. individual) did not affect the outcome, but it’s potential impact on other outcomes could not be evaluated. Although it was not possible to calculate subgroup analyses based on the different diagnostic criteria used for inclusion of CFS patients, most included studies used well-established criteria [2]. For the two studies that used cut-off values as inclusion criteria, sensitivity analyses did not indicate a significant impact on results. Furthermore, the influence of three variables of treatment intensity was examined: treatment dosage (total time in minutes), the number of sessions, and the duration of treatments in weeks. There was an effect of treatment dosage, as expected, for fatigue (higher dosage predicts a higher symptom reduction), and the moderator accounted for almost all heterogeneity (R2 = 91.17%). Although the included studies evaluated relatively short therapies with a range from 2 to 17 sessions, the number of sessions was a significant moderator for the effect in perceived health status. Duration of treatment (in weeks) neither affected efficacy nor acceptance. That is, treatment intensity may be a relevant moderator in CFS. Consequently, two indicators of treatment intensity each showed a relevant association with one of the two most frequently studied efficacy outcome measures. In contrast, they were not associated with the measures of treatment acceptance. Fatigue severity was associated with a higher non-completion rate – that is, if the mean on the fatigue scale rises one point, the proportion of non-completion rises 0.1. This was also true for drop-out, but to a lesser extent. That is, some individuals might not deem themselves able to participate in regular sessions due to their severe fatigue symptoms. Duration of symptoms at baseline neither moderated non-completion nor drop-out. The differentiated sensitivity analyses, which considered the meta-analytic model choice and the influence of specific studies indicated that the project’s results are robust. Additionally, there was no substantial indication of publication bias for the efficacy outcomes.
What the sources say
- Partly supportedcites [16] Ingman T, Smakowski A, Goldsmith K, Chalder T. A systematic literature review of randomized controlled trials evaluating prognosis following treatment for adults with chronic fatigue syndrome. Psychol Med. 2022;52:2917–29. https://doi.org/10.1017/S0033291722002471. sourceExperimental — accuracy not yet measured
The Results (Table 4; page unavailable) report global worsening in 11% of CBT participants, versus 19% of controls, supporting the description of worsening as relatively uncommon. But the measure includes ratings of ‘a little worse,’ rather than establishing clinically relevant symptom worsening, and the review describes worsening following CBT, not necessarily caused by it. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
71 more claims · 6 with their cited sources checked
Create a free account to see all 144 claims and to verify the 2 references still open.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 29
- The quote only partly states this claim. 2
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study
Fukuda, K., Straus, S. E., Hickie, I., Sharpe, M. C., Dobbins, J. G., Komaroff, A., & and International Chronic Fatigue Syndrome Study Group. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-12-199412150-00009 · Cited by 4,969
Eysenbach, G. (2005) · Journal of Medical Internet Research · doi:10.2196/jmir.7.1.e11 · Cited by 2,524 · cited 1×
“It is possible that it leads to a form of selection bias within randomized controlled trials [18], when people refuse to start or finish a therapy.”
A report—Chronic fatigue syndrome: Guidelines for research
Sharpe, M. C. (1991) · Journal of the Royal Society of Medicine · doi:10.1177/014107689108400224 · Cited by 1,026 · cited 3×
“Consequently, the statements made apply primarily to CFS according to the Oxford criteria [22] and Centers for Disease Control and Prevention (CDC) definition [1], but not for myalgic encephalomyelitis/CFS according to the definition by the NICE guidelines [14].”
Premature discontinuation in adult psychotherapy: A meta-analysis
Swift, J. K., & Greenberg, R. P. (2012) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0028226 · Cited by 978 · cited 1×
“In general, about one fifth of participants drop out of psychotherapy trials [28, 52].”
White, P., Goldsmith, K., Johnson, A., Potts, L., Walwyn, R., DeCesare, J., Baber, H., Burgess, M., Clark, L., Cox, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60096-2 · Cited by 897
Dropout from Internet‐based treatment for psychological disorders
Melville, K. M., Casey, L. M., & Kavanagh, D. J. (2010) · British Journal of Clinical Psychology · doi:10.1348/014466509x472138 · Cited by 597 · cited 1×
“Although some clinicians argue that some patients discontinue treatment due to major improvements already made during the current path of treatment, this is rather unlikely [51].”
Meta-analysis of dropout from cognitive behavioral therapy: Magnitude, timing, and moderators.
Fernandez, E., Salem, D., Swift, J. K., & Ramtahal, N. (2015) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000044 · Cited by 551 · cited 5×
“On the other hand, treatment refusal was defined as the proportion of participants in each group that did not start the intervention after being allocated and thus did not complete any module: ( n participants not starting treatment) / ( n participants allocated to intervention group) [28].”
InfluentialCuijpers, P., Noma, H., Karyotaki, E., Vinkers, C. H., Cipriani, A., & Furukawa, T. A. (2020) · World Psychiatry · doi:10.1002/wps.20701 · Cited by 540
Research works printed but not linked: 2
- Martin A, Härter M, Henningsen P, Hiller W, Kröner-Herwig B, Rief W. Evidenzbasierte Leitlinie zur Psychotherapie somatoformer Störungen und assoziierter Syndrome [Evidence-based guideline for psychotherapy for somatoform disorders and associated syndromes]. Göttingen: Hogrefe; 2013.
- Turnbull N, Shaw EJ, Baker R, et al. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) in adults and children. London: Royal College of General Practitioners; 2007. p. 2007.
Cited by
Brief Outpatient Rehabilitation Program for Post–COVID-19 Condition
Nerli, T. F., Selvakumar, J. P., Cvejic, E., Heier, I., Pedersen, M., Johnsen, T. L., & Wyller, V. B. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.50744 · Cited by 42
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management
Fan, J., Jiao, J., Chang, H.-Q., Zhong, D., Liu, X.-B., Li, J., Chen, L., Jin, R., & Wu, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07506-y · Cited by 16
“A meta-analysis of 15 randomized controlled trials (RCTs) revealed that CBT effectively relieved fatigue, depression, and anxiety, with long-term improvements and high adherence [162].”
Bermpohl, F. M. G., & Martin, A. (2025) · Psychotherapy and Psychosomatics · doi:10.1159/000544825 · Cited by 14
Self-citationMartín, A. D. V., Salazar, A. D., Pérez, I. M. M., & Pérez, S. E. M. (2025) · International journal of exercise science · doi:10.70252/daya4589 · Cited by 9
Sangalli, L., Gilmore, G. R., Moreno‐Hay, I., Whitehurst, L. N., Alessandri‐Bonetti, A., & Boggero, I. A. (2025) · CRANIO® · doi:10.1080/08869634.2025.2476606 · Cited by 7
“The effectiveness of behavioral interventions in improving headache disability, fatigue, and quality of life aligns with similar literature [93–97].”
Metadata
- Authors
- Maas genannt Bermpohl, F., Kucharczyk-Bodenburg, A.-C., & Martin, A.
- Affiliations
- University of Wuppertal (DE)
- Venue
- International Journal of Behavioral Medicine
- Published
- 2024-01-16
- Volume
- 31
- Issue
- 6
- Pages
- 895-910
- ISSN
- 1070-5503 (ISSN-L)
- 1532-7558
- PMC
- PMC11588766
- OpenAlex
- W4390901176
- Cited by
- 29
- References
- 58
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 5
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- International Journal of Behavioral Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
- Funders
- Bergische Universität Wuppertal
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Keywords
- cognitive behavioral therapy, chronic fatigue syndrome, treatment efficacy, treatment acceptability, medication adherence, dropout rates, fatigue, depression, anxiety, health perception, long-term follow-up
- MeSH terms
- Adult, Anxiety, Depression, Humans, Patient Acceptance of Health Care, Fatigue Syndrome, Chronic, Cognitive Behavioral Therapy, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Acceptance of Cognitive Behavioral Therapy in Adults with Chronic Fatigue Syndrome: A Meta-analysis. https://app.cochat.ai/papers/10.1007/s12529-023-10254-2
- The paper
- Maas genannt Bermpohl, F., Kucharczyk-Bodenburg, A.-C., & Martin, A. (2024). Efficacy and Acceptance of Cognitive Behavioral Therapy in Adults with Chronic Fatigue Syndrome: A Meta-analysis. International Journal of Behavioral Medicine. https://doi.org/10.1007/s12529-023-10254-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.